Abstract Body: Introduction: Control of hypertension is often hard for people with chronic kidney disease (CKD) because nitric oxide (NO) is not available to the same extent. Giving nitrate supplements or L-arginine as targeted therapies may be a new way to lower blood pressure (BP) in hypertensive kidney disease. To this point, the effects of NO-enhancing interventions on this group have not been reviewed. We reviewed studies to investigate NO-based approaches for reducing BP in patients with CKD and hypertension.
Hypothesis: Treatment of CKD patients with resistant hypertension will provide greater benefits if NO is restored in personalized and time-restricted ways, following their individual NO patterns at times of natural NO reduction in the body.
Methods: Using PRISMA guidelines, we included clinical studies from hypertensive CKD groups that studied nitric oxide donor or precursor therapeutics. The analysis included 5 randomized controlled trials and 6 observational studies. Treatments provided included inorganic nitrate, amino acid precursors of NO, and various strategies to increase NO levels. We looked at changes in blood pressure, the function of blood vessel walls, and kidney markers as the main outcomes. The Cochrane Risk of Bias tool was used to judge the quality of randomized controlled trials, and Newcastle-Ottawa Scale was used for observational studies.
Results: Most of the NO-enhancing treatments tested minimally reduced CKD patients' BP. In some small RCTs, people taking nitrate from beetroot juice or L-arginine experienced lower BP and better endothelial function markers than the control participants. According to observational studies, having more NO bioavailability leads to betterBP and a slower development of kidney disease, though other factors may affect the results. The research was of moderate value; specialized studies still had limited participants. However, the results showed the same trend, and observational work showed the reasons behind NO's role in widening blood vessels.
Conclusions: The findings in this systematic review fill a gap by showing evidence that regulating nitric oxide signaling can help control BP in CKD patients. What's unique about these discoveries is how they look at patients with severe hypertension who have less NO. Although our results are inconclusive, non-targeted therapies could be helpful for patients with hypertensive CKD, requiring careful testing in larger studies to confirm both safety and effectiveness.